What is Gilead Sciences, Inc. Annual Revenue?

Gilead Sciences, Inc. Annual Revenue rose 6.04%, in the last year to $28,754 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

What is Gilead Sciences, Inc. Annual Net Profit?

Gilead Sciences, Inc. Annual Net Profit fell 91.53% in the last year to $480 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is Gilead Sciences, Inc. Price to Earning Ratio?

Gilead Sciences, Inc. Price to Earning Ratio is 270.96, higher than its sector PE ratio of 3.14.

What is Gilead Sciences, Inc. Stock Price?

Gilead Sciences, Inc. Stock Price rose 56.28% and outperformed its sector by 49.47% in the past year.

What is Gilead Sciences, Inc. Quarterly Revenue?

Gilead Sciences, Inc. Quarterly Revenue rose 6.4% YoY to $7,569 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

What is Gilead Sciences, Inc. Quarterly Net profit?

Gilead Sciences, Inc. Quarterly Net profit rose 24.77% YoY to $1,783 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

What is Gilead Sciences, Inc. Debt to Equity Ratio?

Gilead Sciences, Inc. Debt to Equity Ratio of 1.38 is higher than 1. This implies that company assets are financed through debt.

What is Gilead Sciences, Inc. Return on Equity(ROE)?

Gilead Sciences, Inc. Return on Equity(ROE) for the last financial year was 2.28%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Gilead Sciences, Inc. Mutual Fund Holding?

Gilead Sciences, Inc. Mutual Fund Holding decreased by 1.01% in the last quarter to 76.33.

What is Gilead Sciences, Inc. Promoter Share Holding?

Gilead Sciences, Inc. Promoter Share Holding increased by 0.02% in the most recent quarter to 0.09%.

What is Gilead Sciences, Inc. Interest Coverage Ratio?

Gilead Sciences, Inc. Interest Coverage Ratio is 1.71, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is Gilead Sciences, Inc. Institutional Holding?

Gilead Sciences, Inc. Institutional Holding increased by 0.18% in the last quarter to 86.15.

How is the Gilead Sciences, Inc. today?

The Gilead Sciences, Inc. today is trading in the down by -0.20% at 104.33.

How has Gilead Sciences, Inc. performed historically?

The Gilead Sciences, Inc. is currently trading down -0.20% on an intraday basis in the past week the index rose 0.68%. The index has been up 13.60% in the past quarter and rose 56.28% in the past year. You can view this in the overview section.

Gilead Sciences, Inc. XNAS: GILD

Gilead Sciences, Inc. Live Share Price Today, Share Analysis and Chart

Name: Gilead Sciences, Inc.: Is Infosys Ltd. worth buying?
Item: Gilead Sciences, Inc.
Rating: 2.027111
Author: Trendlyne DVM scores

Expensive Performer

Download real time

104.33 -0.21 (-0.20%)

68.08% Gain from 52W Low

6.6M XNAS Volume

XNAS 21 Apr, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Gilead Sciences, Inc. is on 25 Apr 2025 for the purpose of Gilead Sciences Inc First Quarter Earnings Results for 2025 See details

Gilead Sciences, Inc. Key Metrics

My Metrics

Default

Market Capitalization Market Runner Up Unavailable in chosen country	130,061.4
PE TTM High in industry Unavailable in chosen country	271
PEG TTM Negative PEG TTM Unavailable in chosen country	-3
Price to Book High in industry Unavailable in chosen country	6.7
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	86.1
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	6.4
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	6
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	24.8
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-91.5
Operating Profit Margin Qtr % High in industry Unavailable in chosen country	32.2
Operating Profit Margin TTM % High in industry Unavailable in chosen country	28.1
Piotroski Score High in industry Unavailable in chosen country	6
Rel Perf vs Sector quarter% Unavailable in chosen country	14.2
ROE Annual % High in industry Unavailable in chosen country	2.3
RoA Annual % High in industry Unavailable in chosen country	0.8

All financials are in USD Million and price data in USD

Medium Financial Strength

44.4 / 100

Expensive Valuation

21.0 / 100

Technically Neutral

52.3 / 100

Expensive Performer These stocks are with medium quality and mid-range technical aspects. However, their financials make them little expensive so choose the right moment to buy them. View Similar Embed DVM

113

1Yr Price target upside is 8%

25 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Strong Sell Zone

91.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Gilead Sciences, Inc. Stock Price Analysis

Day Price Range -0.2% 1 Day return Unavailable in chosen country	104.3 (LTP) 103.1105.2 LowHigh
Week Price Range 0.7% 1 Week return Unavailable in chosen country	104.3 (LTP) 103.1107.2 LowHigh
Month Price Range -1.4% 1 Month return Unavailable in chosen country	104.3 (LTP) 97.3114.8 LowHigh
52 Week Price Range 56.3% 1 Year return Unavailable in chosen country	104.3 (LTP) 62.1120 LowHigh

View full Share Price History

Gilead Sciences, Inc. Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Gilead Sciences, Inc.'s Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

0.4

Avg. Estimate

6.2

Low Estimate

High Estimate

6.6

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 1534.2% in FY25

Consensus Recommendation

30 ANALYST Recommendations

BUY

The consensus recommendation from 30 analysts for Gilead Sciences, Inc. is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Gilead Sciences, Inc. Stock Analysis

Gilead Sciences, Inc. stock analysis with key metrics, changes, and trends.

Gilead Sciences, Inc. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$28,754 M	6.04%	positive	Annual Revenue rose 6.04%, in the last year to $28,754 M. Its sector's average revenue growth for the last fiscal year was 7.49%.
Annual Net Profit	$480 M	91.53%	negative	Annual Net Profit fell 91.53% in the last year to $480 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	270.96	-	negative	Price to Earning Ratio is 270.96, higher than its sector PE ratio of 3.14.
Stock Price	$104.33	56.28%	positive	Stock Price rose 56.28% and outperformed its sector by 49.47% in the past year.
Quarterly Revenue	$7,569 M	6.4%	positive	Quarterly Revenue rose 6.4% YoY to $7,569 M. Its sector's average revenue growth YoY for the quarter was 5.79%.
Quarterly Net profit	$1,783 M	24.77%	positive	Quarterly Net profit rose 24.77% YoY to $1,783 M. Its sector's average net profit growth YoY for the quarter was -41.98%.
Debt to Equity Ratio	1.38	-	negative	Debt to Equity Ratio of 1.38 is higher than 1. This implies that company assets are financed through debt.
Return on Equity(ROE)	2.28 %	2.28%	negative	Return on Equity(ROE) for the last financial year was 2.28%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	76.33 %	-1.01%	negative	Mutual Fund Holding decreased by 1.01% in the last quarter to 76.33.
Promoter Share Holding	0.09 %	0.02%	positive	Promoter Share Holding increased by 0.02% in the most recent quarter to 0.09%.
Interest Coverage Ratio	1.71	-	positive	Interest Coverage Ratio is 1.71, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
Institutional Holding	86.15 %	0.18%	positive	Institutional Holding increased by 0.18% in the last quarter to 86.15.

VIEW LESS

Loading data..

Gilead Sciences, Inc. - Company Profile

What does Gilead Sciences, Inc. do?

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences, Inc. Management structure

All Gross Remunerations are in USD

Ms. Diane E. Wilfong

Interim Corporate Controller and Interim Chief Accounting Officer

2025

Gross Remuneration

Year

Ms. Sandra Patterson

Senior Vice President, Corporate Controller and Chief Accounting Officer

2025

424.71 K

2024

Gross Remuneration

Year

Gilead Sciences, Inc. Live Share Price Today, Share Analysis and Chart

68.08% Gain from 52W Low

Gilead Sciences, Inc. Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Gilead Sciences, Inc. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Gilead Sciences, Inc. Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Gilead Sciences, Inc.'s Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to grow by 1534.2% in FY25

Consensus Recommendation

The consensus recommendation from 30 analysts for Gilead Sciences, Inc. is BUY

Gilead Sciences, Inc. Stock Analysis

Gilead Sciences, Inc. stock analysis with key metrics, changes, and trends.

Annual Revenue rose 6.04%, in the last year to $28,754 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit fell 91.53% in the last year to $480 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is 270.96, higher than its sector PE ratio of 3.14.

Stock Price rose 56.28% and outperformed its sector by 49.47% in the past year.

Quarterly Revenue rose 6.4% YoY to $7,569 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit rose 24.77% YoY to $1,783 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Debt to Equity Ratio of 1.38 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE) for the last financial year was 2.28%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 1.01% in the last quarter to 76.33.

Promoter Share Holding increased by 0.02% in the most recent quarter to 0.09%.

Interest Coverage Ratio is 1.71, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding increased by 0.18% in the last quarter to 86.15.

Gilead Sciences, Inc. - Company Profile

What does Gilead Sciences, Inc. do?

Gilead Sciences, Inc. Management structure

Ms. Diane E. Wilfong

Interim Corporate Controller and Interim Chief Accounting Officer

Ms. Sandra Patterson

Senior Vice President, Corporate Controller and Chief Accounting Officer

Gilead Sciences, Inc. Board of directors

Dr. Ted W. Love, M.D.

Independent Director

Mr. Anthony Welters

Lead Independent Director

Ms. Kelly Anne Kramer

Independent Director

Dr. Jacqueline K. Barton, PhD

Independent Director

Dr. Sandra J. Horning, M.D.